The Gamaleya Center announced the deadlines for registering a nasal vaccine against COVID-19

Clinical study of an internasal CORONAVIRUS vaccine developed at the Center. N.F. Gamalei, will begin in late 2021 - early 2022, it is planned to register the drug in 2022. This was reported to TASS by the DIRECTOR of the Center Alexander Gintsburg.

“Preclinical studies are currently underway. We plan to enter the clinic at the end of this year or the beginning of next year, with access to its registration based on the results of the study in 2022,” Gunzburg said.

According to him, the Center Gameley is working in several areas in terms of creating and improving vaccines against coronavirus.

The Center has developed the Sputnik V vaccine, which was registered in RUSSIA in August and approved for use in 65 countries, as well as the one-component Sputnik Light vaccine, which was registered in early May.